Imago Biosciences Inc

Imago Biosciences — Technical Presentation (December 2021)

19 slides from Imago Biosciences's technical presentation, Dec 13, 2021

  1. Slide 1: Disclosures

    Abstract #139: Bomedemstat in MF Disclosures Gill H – Nothing to disclose Bomedemstat is an investigational drug that has not yet been approved by the US Food and Drug Administration and is only available through clinical trial participation Exhibit 99.2

  2. Slide 2: A Phase 2 Study of IMG-7289 (Bomedemstat) in Patients with Advanced Myelofibrosis

    A Phase 2 Study of IMG-7289 (Bomedemstat) in Patients with Advanced Myelofibrosis Harinder Gill, MBBS, MD, FRCP, FRCPath1, Abdulraheem Yacoub, MD2, Kristen M. Pettit, MD3, Terrence Bradley, MD4, Aaron T. Gerds, MD, MS5, Maciej Tatarczuch, BMBS6, Jake Shortt, FRACP, FRCPA, PhD7, Natasha Joan Curtin,

  3. Slide 3: LSD1 is a key regulator of hematopoietic differentiation

    LSD1 is a key regulator of hematopoietic differentiation LSD1 (Lysine-specific demethylase 1) demethylates H3K4 and other chromatin-associated proteins, e.g., p53 Loss of LSD1 activity is associated with loss of self-renewal in malignant HSCs1 LSD1 is required for the differentiation of megakaryocyt

  4. Slide 4: Introduction to Bomedemstat

    Introduction to Bomedemstat Bomedemstat is an irreversible inhibitor of LSD1 Discovered and developed by Imago PK and dose-response data suggest once-daily dosing No apparent penetration across the blood-brain barrier Bomedemstat has been evaluated in 170+ patients with advanced myeloid malignancies

  5. Slide 5: Study Design

    Study Design Safety and tolerability Pharmacokinetics in first 15 patients Spleen volume reduction Primary Endpoints Key Eligibility Criteria Secondary Endpoints Symptom reduction (MPN-SAF TSS) Changes in cytokine profiles Changes in mutant allele frequencies (MAF) Changes in bone marrow (BM) fibros

  6. Slide 6: Bomedemstat Treatment Plan

    Bomedemstat Treatment Plan IMG-7289 (bomedemstat) PO once daily (QD) Each patient dose-titrated to a target platelet count of 50-75 x 109/L Phase 1/2a Starting Dose was 0.25 mg/kg (QD) (N=18) Phase 2b Starting Dose was 0.5 mg/g (N = 25) and, later, 0.6 mg/kg (N = 46) QD Abstract #139: Bomedemstat in

  7. Slide 7: Enrollment Status and Patient Disposition

    Enrollment Status and Patient Disposition Abstract #139: Bomedemstat in MF Phase 1/2a (N=18) Completed 12 Weeks Reason Off Treatment Pre- Wk 12 (N=3) Week 12 15 (83%) Adverse Event = 2 Limited Clinical Benefit = 1 Median Duration of Treatment: 165 days (range 27-562) Phase 2b (N=71*) Completed 24 We

  8. Slide 8: Baseline Characteristics: Most are high risk and heavily pre-treated

    Baseline Characteristics: Most are high risk and heavily pre-treated Abstract #139: Bomedemstat in MF Characteristic N = 89 Median age (range) 68 (35– 88) Male 46 (52%) Disease subtype PMF Post-ET MF Post-PV MF 41 (46%) 30 (34%) 18 (20%) IPSS Risk Classification Intermediate-1 Intermediate-2 High Mi

  9. Slide 9: Safety and Tolerability

    Safety and Tolerability Bomedemstat is generally well tolerated Most common hematologic AE, thrombocytopenia, is anticipated because dose titration rules target Grade 2 (50-75 x 109/L) The most common non-hematologic AE related to bomedemstat was dysgeusia (n=27, 30% of patients) with 1 patient who

  10. Slide 10: Total Symptom Score (TSS) at weeks

    Total Symptom Score (TSS) at 24 weeks Changes in MPN-SAF TSS – Patients with significant symptom burden (≥20) % Change @ 24 ± 2 weeks 17/23 (74%) had a decrease in TSS 6/23 (26%) had a decrease of ≥50% Absolute Change @ 24 ± 2 weeks Abstract #139: Bomedemstat in MF Data cut-off date: 31Oct 2021 Plac

  11. Slide 11: Spleen Volume Reduction at Weeks

    Spleen Volume Reduction at 24 Weeks Abstract #139: Bomedemstat in MF Change in Spleen Volume % Change @ 24 ± 2 weeks Absolute Change @ 24 ± 2 weeks All spleen sizes allowed at study entry 30/40 (75%) had any decrease 14/40 (35%) had ≥20% decrease 3/40 (8%) had ≥35% decrease 97 & 107% Data cut-off da

  12. Slide 12: Changes in Hemoglobin

    Changes in Hemoglobin Abstract #139: Bomedemstat in MF * Exclusions due to: ET prior to Wk12 In patients (N=36*) who were transfusion-independent at baseline, at 12 weeks: 89% (32/36) had stable or improved Hb 44% (16/36) had an increase ≥1.0 g/dL 44% (16/36) had stable Hb ∆ <±1.0 g/dL In patients (

  13. Slide 13: Impact on Mutant Alleles

    Standard deviation in this study at a read depth of 1000 is ~5% Change defined as ≥5% for heterozygotes, ≥10% for increase/ ≥2.5% decrease for homozygous clones for up to >600 days Change from pre-dose to last timepoint on drug ± 2days Impact on Mutant Alleles 261 genes serially sequenced by NGS to

  14. Slide 14: Conclusions

    Conclusions Generally safe and well tolerated to date Shows improvements in symptom scores, spleen volumes, and anemia 81% of allele frequencies are stable or decreased including driver and HMR mutations such as ASXL1 No new mutations or transformation to AML in patients with a high-risk of progress

  15. Slide 15: Thank you to Investigators and Study Participants!

    Thank you to Investigators and Study Participants! Abstract #139: Bomedemstat in MF Investigators - APAC Harry Gill – QMH, Hong Kong David Ross – Royal Adelaide, AU Will Stevenson – Royal North Shore, Sydney, AU Kate Burbury – Peter MacCallum, Melbourne. AU Jake Shortt – Monash U., Melbourne, AU Mac

  16. Slide 16: Back-Up Slides

    Back-Up Slides

  17. Slide 17: Bomedemstat Treatment Plan – Back-Up Slide

    Bomedemstat Treatment Plan – Back-Up Slide IMG-7289 (bomedemstat) PO once daily Each patient dose-titrated to a target platelet count of 50-75 x 109/L Starting dose was initially 0.25 mg/kg once daily for the Phase 1/2a (N=18), and then 0.5 mg/g (N = 25) and 0.6 mg/kg once daily in the Phase 2b (N=

  18. Slide 18: Changes in Transfusion Frequency

    Changes in Transfusion Frequency Abstract #139: Bomedemstat in MF Change in Transfusion Burden in Transfusion-Dependent Patients (N=17**) Transfusion Independent 1 (6%) Improved (≥1 unit/mo decrease) 2 (12%) Stable (∆<1 unit/mo) 7 (41%) Worsening (≥1 unit/mo increase) 7 (41%) **Exclusions due to: ET

  19. Slide 19: Reduction in Inflammatory Chemokines

    Reduction in Inflammatory Chemokines Abstract #139: Bomedemstat in MF CCL5 (RANTES) is chemokine secreted in bone marrow by activated T cells.

Imago BioSciences — Technical Presentation (December 2021) on 6ix